Glycaemic control, cardiovascular disease, and mortality in type 2 diabetes

The Lancet

Volumn 384, Issue 9958, 2014, Pages 1906-1907

  Chiasson, Jean Louis ^a   Lorier, Jacques Le ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; ANTIDIABETIC AGENT;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; DIABETIC NEUROPATHY; GLYCEMIC CONTROL; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INTENSIVE CARE; ISCHEMIC HEART DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; POST HOC ANALYSIS; PREVALENCE; RISK FACTOR; UNSTABLE ANGINA PECTORIS; DIABETES MELLITUS, TYPE 2; DIABETIC CARDIOMYOPATHIES; FEMALE; MALE; MYOCARDIAL INFARCTION;

DIABETES MELLITUS, TYPE 2; DIABETIC CARDIOMYOPATHIES; FEMALE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; MYOCARDIAL INFARCTION;

EID: 84919416075     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)60884-9     Document Type: Note

References (16)

1. UK Prospective Diabetes Study Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 1998 837 853
2. HC Gerstein, ME Miller, RP Byington et al. Effects of intensive glucose lowering in type 2 diabetes N Engl J Med 358 2008 2545 2559
3. A Patel, S MacMahon, J Chalmers et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes N Engl J Med 358 2008 2560 2572
4. MC Riddle, WT Ambrosius, DJ Brillon et al. Epidemiologic relationships between A1C and all-cause mortality during a median 3·4-year follow-up of glycemic treatment in the ACCORD trial Diabetes Care 33 2010 983 990
5. R Pop-Busui, GW Evans, HC Gerstein et al. Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial Diabetes Care 33 2010 1578 1584
6. DE Bonds, ME Miller, RM Bergenstal et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study BMJ 340 2010 b4909
7. JM Lachin Point: intensive glycemic control and mortality in ACCORD - a chance finding? Diabetes Care 33 2010 2719 2721
8. HC Gerstein, ME Miller, F Ismail-Beigi for the ACCORD Study Group Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial Lancet 2014 published online Aug 1. http://dx.doi.org/10.1016/S0140-6736(14)60611-5
9. W Duckworth, C Abraira, T Moritz et al. Glucose control and vascular complications in veterans with type 2 diabetes N Engl J Med 360 2009 129 139
10. RR Holman, SK Paul, MA Bethel, DR Matthews, HA Neil 10-year follow-up of intensive glucose control in type 2 diabetes N Engl J Med 359 2008 1577 1589
11. FM Turnbull, C Abraira, RJ Anderson et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes Diabetologia 52 2009 2288 2298
12. P Gaede, H Lund-Andersen, HH Parving, O Pedersen Effect of a multifactorial intervention on mortality in type 2 diabetes N Engl J Med 358 2008 580 591
13. American Diabetes Association Standards of medical care in diabetes - 2014 Diabetes Care 37 suppl 1 2014 S14 S80
14. Y Winhofer, M Krssak, D Jankovic et al. Short-term hyperinsulinemia and hyperglycemia increase myocardial lipid content in normal subjects Diabetes 61 2012 1210 1216
15. D Jankovic, Y Winhofer, M Promintzer-Schifferl et al. Effects of insulin therapy on myocardial lipid content and cardiac geometry in patients with type-2 diabetes mellitus PLoS One 7 2012 e50077
16. B Gaborit, I Abdesselam, A Dutour Epicardial fat: more than just an "epi" phenomenon? Horm Metab Res 45 2013 991 1001